Yacoub Irshaid MD, PhD, ABCP Department of Pharmacology

Definitions:

 The WHO defines an adverse drug reaction (ADR) as "a response to a drug that is noxious and unintended and occurs at doses normally used in man for the prophylaxis, diagnosis or therapy of disease, or for modification of physiological function".

- The use of the phrase 'at doses normally used in man' distinguishes the noxious effect during normal medical use from the toxic effect caused by poisoning (over dose).
- There is <u>no need</u> to prove a pharmacological mechanism for any noxious response to be termed as ADR.

- The term "side effect" is distinct from ADR.
- A side effect is an unintended effect of a drug related to its pharmacological properties and can include unexpected benefits of treatment.

- The WHO definition has been criticized for excluding the potential for contamination of the product (dosage form) and ADRs associated with pharmacologically inactive excipients in the product.
- The use of the term 'drug' also excluded the use of complementary and alternative treatments such as herbal products.

- In an attempt to overcome these issues, the following definition of ADR was proposed:
 - "A harmful or unpleasant reaction, resulting from the <u>intervention</u> related to the use of a medicinal <u>product</u>, which:
- 1. predicts hazard for future administration.
- 2. warrants prevention or specific treatment.
- 3. requires alteration of dosage regimen.
- 4. requires withdrawal of the product.

- It is also important to avoid confusion with the term "adverse drug event (ADE)".
- ADE is an adverse outcome that occurs after the use of the drug, which may or may not be linked to this use.
- Therefore, all ADRs are ADEs, but not all ADEs will be ADRs.

- ADE can be used when it is <u>NOT</u> possible to suggest a <u>causal link</u> between a drug treatment and an adverse outcome.
- The suspicion of a causal relationship between the drug and the adverse effect is central to the definition of an ADR.

Epidemiology of ADRs:

- 1. ADRs are responsible for 2.6% 6.5% of admissions to hospitals.
- 2. 3.5-14.7% of inpatients develop ADRs.
- 3. 2.3% of patients die as a result of ADRs.
- 4. In primary care, estimates of the incidence of ADRs range from 25-30%.
- 5. ADRs are the 4th 6th leading cause of death in USA.

Stay in hospital for patients having ADR was ~
 20 days compared to ~ 8 days without ADRs, leading to escalation of cost.

Rawlins-Thompson Classification of ADRs:

- 1. Type A: is an exaggerated (augmented) pharmacological effects of the drug. It is predictable, dose-dependent, common (80% of all ADRs), preventable, low morbidity and mortality.
- Example: bradycardia associated with β-adrenergic blockers.

- 2. Type B: abnormal (bizzare) effects not related to the pharmacological effects of the drug, more serious, could be fatal, often discovered after marketing of the drug, uncommon, unpredictable, not dose-dependent, high morbidity and mortality
- Examples: hepatotoxicity of isoniazid, and allergic reactions to drugs.

- 3. Type C: dose-related and time related: uncommon, related to the cumulative dose.
- Example: Hypothalamic-pituitary adrenal axis suppression by corticosteroids.
- 4. Type D: uncommon, time-related, usually dose related, occurs or becomes apparent some time after the use of the drug (delayed effect).
- Example: carcinogenesis

- 5. Type E (end of use): occurs soon after withdrawal of the drug, uncommon.
- Example: opiate withdrawal syndrome.
- Type F (unexpected failure of therapy): common, dose-related, often caused by drug interactions.
- Example: failure of contraceptives in the presence of metabolizing enzyme inducers.

Factors affecting susceptibility to ADRs:

1. Age:

Elderly patients:

 are more prone to ADRs because of age-related decline in both metabolism and elimination of drugs from the body. They also have multiple co-morbidities and thus more prescribed drugs.

Children:

- 1. Differ from adults in drug response.
- 2. Neonatal differences in body composition, metabolism, and other physiological parameters increase the risk of specific ADRs.
- 3. Higher body water content can increase the volume of distribution of water soluble drugs.
- 4. Reduced albumin may be associated with high free concentrations of highly protein-bound drugs.

- 5. Immature blood-brain barrier can increase sensitivity to morphine and other drugs.
- Differences in drug metabolism and elimination and end-organ responses can increase risk.
- Chloramphenicol, digoxin, and ototoxic antibiotics have higher risks of toxicity in the first weeks of life.

Older children:

- are more susceptible to some ADRs:
- 1. Increased risk of extrapyramidal effects associated with metoclopramide.
- 2. Use of aspirin is restricted under age of 12 years because of association with Reye's syndrome.
- 3. Heightened probability of dosing errors and the relative lack of evidence for both safety and efficacy put children at high risk.

2. Gender:

- Women may be more susceptible to ADRs.
- Some ADRs are more common in women than men:
- 1) Impairment of concentration and psychiatric adverse events associated with anti-malarial agent mefloquine.
- 2) Drug-induced torsade de pointes, may be because of their longer QTc interval compared to men.

3. Co-morbidities and concomitant drug use:

- Reduction in hepatic and renal functions increase the risk of ADRs.
- Co-morbidities such as congestive heart failure, diabetes, and peripheral vascular, chronic pulmonary, rheumatological, hepatic, renal, and malignant diseases were strong predictors of readmissions for ADRs.

 That might be due to pharmacokinetic or pharmacodynamic changes in these diseases, or drug interactions due to multiple therapy.

4. Ethnicity:

- This is related to ADRs due to inherited traits of metabolism, and environmental factors.
- There is increased risk of angioedema with the use of ACE-inhibitors in Africans.
- Increased susceptibility of whites and blacks to CNS adverse effects of mefloquine compared to Chinese and Japanese.
- Increased risk of myopathy after rosuvastatin in Asians.

- 5. Pharmacogenetics and Pharmacogenomics:
- Pharmacogenetics is the science of understanding how variability in a single gene can influences drug treatment outcomes.
- Pharmacogenomics refer to the collective influence of the genome on individual's drug response profile.
- Genomic Variations introduced the concept of "Personalized Medicine".

- Variation can be caused by different concentrations at sites of drug action – pharmacokinetic variation.
- Or by different responses to the same drug concentration – pharmacodynamics variation.

Genetic variation in drug metabolism:

- 1. Atypical plasma cholinesterase
- 2. Genetic deficiency in acetylation: "slow" "intermediate" and "rapid" acetylators.
- 3. Polymorphic oxidation: ultrarapid, extensive, intermediate or poor metabolizers.

Inherited Variation in Pharmacodynamics:

- 1. Hereditary Warfarin Resistance
- 2. Heparin Resistance
- 3. Vitamin D resistance
- 4. Favism (drug-induced hemolytic anemia)
- 5. Malignant Hyperthermia with Muscle Rigidity
- 6. Glaucoma due to abnormal response to intraocular steroids

Immunological Reactions:

- The immune system is able to recognize drugs as foreign leading to allergic reactions.
- Small molecules can bind to proteins to trigger an immune response, and larger molecules can trigger an immune response directly.
- The immune response is NOT related to the pharmacological action of the drug.
- Prior exposure to the drug is required.

- Allergic reactions range from rashes, serum sickness and angioedema to life-threatening bronchospasm and anaphylaxis.
- Patients with a history of atopic or allergic disorders are at higher risk.
- All types of immunological reaction may occur with drug use: type I (immediate), type II (cytotoxic), type III (immune complex) and type IV (delayed).

Causality Assessment:

 Causality is very difficult to prove and a high degree of suspicion is all that is needed for "Regulatory Authority" action.

- An objective method to assess causality that reduce assessor bias is the "Naranjo algorithm".
- It uses a questionnaire, and points are added or subtracted based on responses to each question.
- The total score is then used to place assessment as: highly probable, probable, possible, or doubtful.

| | Question | Yes | No | Do Not Know | Score |
|--|---|-----|----|-------------|-------|
| 1. Are there previous conclusive reports on this reaction? | | +1 | 0 | 0 | |
| 2. Did the adverse event appear after the suspected drug was administered? | | +2 | -1 | 0 | |
| Did the adverse reaction improve when the drug was discontinued or a specific antagonist was administered? | | +1 | 0 | 0 | |
| 4. Did the adverse event appear when the drug was readministered? | | +2 | -1 | 0 | |
| 5. Are there alternative causes (other than the drug) that, on their own, could have caused the reaction? | | -1 | +2 | 0 | |
| 6. Did the reaction reappear when a placebo was given? | | -1 | +1 | 0 | |
| 7. Was the drug detected in the blood (or other fluids) in concentrations known to be toxic? | | +1 | 0 | 0 | |
| 8. Was the reaction more severe when the dose was increased or less severe when the dose was decreased? | | +1 | 0 | 0 | |
| 9. Did the patient have a similar reaction to the same or similar drugs in any previous exposure? | | +1 | 0 | 0 | |
| 10. Was the adverse event confirmed by any objective evidence? | | +1 | 0 | 0 | |
| Fotal Score 9 5-8 1-4 0 | ADR Probability Classification Highly Probable Probable Possible Doubtful | | | | |

 $Adapted\ with\ permission\ from:\ Naranjo\ CA, Busto\ U, Sellers\ EM,\ et\ al.\ A\ method\ for\ estimating\ the\ probability\ of\ adverse\ drug\ reactions.\ Clin\ Pharmacol\ Ther\ 1981; 30:239-45.$

Preventing ADRs:

- The majority of ADRs are preventable, thus reducing cost and even death. (How?)
- 1. Checking previous ADR history.
- 2. Minimizing the use of drugs with high risk of developing ADRs.
- 3. Tailoring drug selection to individuals based on factors that predispose to ADRs.

- 4. Rational prescribing.
- 5. <u>Improved sharing of information about</u> <u>patient's conditions between health-care</u> <u>providers.</u>
- 6. Monitoring Therapy:
- Monitoring the effect of drugs by <u>measurement of physiological markers</u> or measurement of serum concentration is another method of reducing the risk of ADRs.

- It has been estimated that 25% of preventable drug-related hospital admissions are caused by failure to monitor renal function and electrolytes.
- Clozapine used for management of treatment resistant schizophrenia is associated of significant risk of agranulocytosis, that can be eliminated by mandatory monitoring of white blood cells.

- Advice on monitoring should be clear, provide an evidence-based frequency of monitoring, and acceptable outcomes or values.
- 7. Explaining risks to patients:
- Patients have the right to receive understandable information about the potential for ADR, to enable them to make an informed decision

Definition of serious adverse event:

- 1. Results in death.
- 2. Is life-threatening (places the subject at immediate risk of death from the event as it occurred).
- 3. Results in inpatient hospitalization or prolongation of existing hospitalization.
- 4. Results in a persistent or significant disability/incapacity.
- 5. Results in a congenital anomaly/birth defect.

Adverse Events Severity Classification

| Rank | Definition | | |
|----------|---|--|--|
| Mild | Causing no limitation of usual activities. | | |
| | The patient may experience slight discomfort | | |
| Moderate | Causing some limitation of usual activities. | | |
| | The patient may experience annoying discomfort | | |
| Severe | Causing inability to carry out usual activities | | |
| | The patient may experience intolerable discomfort or pain | | |

Adverse Effect Prevalence

| Very common | More than 1/10 of subjects. | | |
|-------------|--------------------------------------|--|--|
| | >10% | | |
| Common | More than 1/100 to less than 1/10. | | |
| | >1% - <10% | | |
| Uncommon | More than 1/1000 to less than 1/100. | | |
| | >0.1% - <1% | | |
| Rare | Less than 1/1000. | | |
| | < 0.1% | | |